Enveric Biosciences, Inc. is an early-development-stage biosciences company. The Company is developing next-generation mental health and oncology treatments using a clinical discovery platform to enable psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. It is developing its product candidates that are focused on cannabinoids derived from non-hemp botanical sources, and synthetic materials containing no tetrahydrocannabinol (THC) in order to comply with United States federal regulations. Its product candidates include EV104, EVM-101, EVM-201, EVM-301, EV102 and EV101. EV104 includes cannabidiol (CBD) and celecoxib conjugate. EVM-101 is a first-generation psychedelic asset, which is a psilocybin oral formulation. EVM-201 is a second-generation psychedelic asset, which is a prodrug of psilocin. EVM-301 is a third-generation psychedelic. EV102 is a cannabinoid cream for topical skin application. EV101 is a cannabinoid plus chemotherapy combination therapy.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)